Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse
Other stock markets
 04:00:34 2024-04-15 pm EDT 		After market 07:58:20 pm
25.91 USD +0.19% Intraday chart for Pfizer, Inc. 25.98 +0.25%
01:17pm News Highlights : Top Financial Services News of the Day - Monday at 7 AM ET DJ
06:15am News Highlights : Top Financial Services News of the Day - Monday at 12 AM ET DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
News Highlights : Top Financial Services News of the Day - Monday at 7 AM ET
DJ
University of Oregon: Options can lower vaccine hesitancy for COVID-19, other diseases
AQ
News Highlights : Top Financial Services News of the Day - Monday at 12 AM ET
DJ
PFIZER INC : JP Morgan remains Neutral
ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US
MT
Skanska announces decreased scope for facility in Everett, Washington, USA, worth USD 49M, about SEK 510M
AQ
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
BU
PFIZER INC : Berenberg remains Neutral
ZD
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease
AQ
Health Care Stocks Steady, Moderna Climbs -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Pfizer : March Social Media Round-Up—Annual Review, International Women’s Day, and a School of Science Celebration
PU
Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2- Directed Antibody-Drug Conjugates in Several Tumor Types
AQ
Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints
MT
Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access
MT
Pfizer: positive results for RSV in adults
CF
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk
DJ
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
BU
Pfizer Inc Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.